follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Medicines Co. acquisition of ProFibrix depends on study

By

Back to Top Comments Email Print

Latest News

advertisement

Parsippany-based The Medicines Co. has announced its intent to purchase Netherlands-based ProFibrix, based on the results of a trial of ProFibrix's powder to stop surgical bleeding.

According to the announcement, Medicines will pay ProFibrix a $10 million upfront option payment. If Medicines is satisfied with the Phase 3 clinical trial results of the powder and decides to proceed, it will purchase all the outstanding capital stock of ProFibrix at closing. Otherwise, Medicines may terminate the transaction with no further obligation to ProFibrix shareholders.

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top